Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T for Relapsed Refractory Malignant Haematological Tumours
NCT06238336Phase 3Recruiting
- Sponsor
- Shanxi Bethune Hospital
- Start
- Jun 2020
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 3 trial of ISIKOK-19 in hematologic malignancy, sponsored by Shanxi Bethune Hospital. Started Jun 2020; status: recruiting.
02
Drugs
ISIKOK-19
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06238336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238336.